Anocca
Pre-clinicalAnocca is creating a pipeline of precision T-cell immunotherapies by combining its novel approach to T-cell biology, cutting-edge biotechnologies and integrated software. Our primary focus is to engineer TCR-T cell therapies for untreatable cancers.
Founded
2014
Focus
BiologicsCell & Gene Therapy
About
Anocca is creating a pipeline of precision T-cell immunotherapies by combining its novel approach to T-cell biology, cutting-edge biotechnologies and integrated software. Our primary focus is to engineer TCR-T cell therapies for untreatable cancers.
Funding History
4Total raised: $47.5M
Series B$25MUndisclosedJun 15, 2021
Series A$10MUndisclosedJun 15, 2019
Series A$10MUndisclosedJun 15, 2018
Seed$2.5MUndisclosedJun 15, 2016
Company Info
TypePrivate
Founded2014
LocationStockholm, Sweden
StagePre-clinical
Contact
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile